– USA, CA – Pyramid, a leading large molecule drug product contract development and manufacturing organization, today announced the appointment of Peter Buzy to its Board of Directors.
About Peter Buzy
Peter Buzy joins the Board of Directors as an accomplished industry executive, having previously served as President and CEO of Paragon Bioservices leading it to a successful sale to Catalent in 2019. Following the sale of Paragon, he served as the Chairman of Catalent’s Gene Therapy Division until 2021. He also currently serves on the boards of AeroSafe Global, Deka Biosciences, and LumaCyte, and is an Advisory Partner at NewSpring Healthcare.
About Pyramid Laboratories, Inc.
Pyramid Laboratories, Inc. is a California-based CDMO focused on formulation development, analytical and stability testing, and aseptic fill-finish manufacturing focused on large molecule therapeutics. Founded in 1988 by CEO Medhat Gorgy and headquartered in Costa Mesa, California, Pyramid operates three leading-edge manufacturing facilities that allow the Company to offer its pharmaceutical and biotech customers a wide range of services, ranging from preclinical development to scale-up aseptic fill-finish commercial manufacturing and distribution.
For more information: https://www.pyramidlabs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
